Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/18797
Tipo
ArtículoDerechos de autor
Acceso abierto
Colecciones
- IOC - Artigos de Periódicos [12488]
Metadatos
Mostrar el registro completo del ítem
DIVERSE INHIBITOR CHEMOTYPES TARGETING TRYPANOSOMA CRUZI CYP51
Autor
Afiliación
University of California San Francisco. Sandler Center for Drug Discovery. San Francisco, CA, USA / University of California San Francisco. Department of Pathology. San Francisco, CA, USA.
University of California San Francisco. Sandler Center for Drug Discovery. San Francisco, CA, USA / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Ultraestrutura Celular. Rio de Janeiro, RJ, Brasil.
University of California San Francisco. Department of Pharmaceutical Chemistry. San Francisco, CA, USA.
University of California San Francisco. Sandler Center for Drug Discovery. San Francisco, CA, USA / University of California San Francisco. Department of Pharmaceutical Chemistry. San Francisco, CA, USA.
University of Western Ontario. King’s University College. London, Ontario, Canada.
University of California San Francisco. Sandler Center for Drug Discovery. San Francisco, CA, USA / University of California San Francisco. Department of Pathology. San Francisco, CA, USA / University of California San Francisco. Department of Medicine. San Francisco, CA, USA.
University of California San Francisco. Sandler Center for Drug Discovery. San Francisco, CA, USA / University of California San Francisco. Department of Pathology. San Francisco, CA, USA.
University of California San Francisco. Small Molecule Discovery Center. San Francisco, CA, USA.
University of California San Francisco. Small Molecule Discovery Center. San Francisco, CA, USA.
University of California San Francisco. Small Molecule Discovery Center. San Francisco, CA, USA.
University of California San Francisco. Small Molecule Discovery Center. San Francisco, CA, USA.
University of California San Francisco. Sandler Center for Drug Discovery. San Francisco, CA, USA / University of California San Francisco. Department of Pathology. San Francisco, CA, USA.
University of California San Francisco. Sandler Center for Drug Discovery. San Francisco, CA, USA / University of California San Francisco. Department of Pathology. San Francisco, CA, USA.
University of California San Francisco. Sandler Center for Drug Discovery. San Francisco, CA, USA / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Ultraestrutura Celular. Rio de Janeiro, RJ, Brasil.
University of California San Francisco. Department of Pharmaceutical Chemistry. San Francisco, CA, USA.
University of California San Francisco. Sandler Center for Drug Discovery. San Francisco, CA, USA / University of California San Francisco. Department of Pharmaceutical Chemistry. San Francisco, CA, USA.
University of Western Ontario. King’s University College. London, Ontario, Canada.
University of California San Francisco. Sandler Center for Drug Discovery. San Francisco, CA, USA / University of California San Francisco. Department of Pathology. San Francisco, CA, USA / University of California San Francisco. Department of Medicine. San Francisco, CA, USA.
University of California San Francisco. Sandler Center for Drug Discovery. San Francisco, CA, USA / University of California San Francisco. Department of Pathology. San Francisco, CA, USA.
University of California San Francisco. Small Molecule Discovery Center. San Francisco, CA, USA.
University of California San Francisco. Small Molecule Discovery Center. San Francisco, CA, USA.
University of California San Francisco. Small Molecule Discovery Center. San Francisco, CA, USA.
University of California San Francisco. Small Molecule Discovery Center. San Francisco, CA, USA.
University of California San Francisco. Sandler Center for Drug Discovery. San Francisco, CA, USA / University of California San Francisco. Department of Pathology. San Francisco, CA, USA.
University of California San Francisco. Sandler Center for Drug Discovery. San Francisco, CA, USA / University of California San Francisco. Department of Pathology. San Francisco, CA, USA.
Resumen en ingles
Chagas Disease, a WHO- and NIH-designated neglected tropical disease, is endemic in Latin America and an emerging infection in North America and Europe as a result of population moves. Although a major cause of morbidity and mortality due to heart failure, as well as inflicting a heavy economic burden in affected regions, Chagas Disease elicits scant notice from the pharmaceutical industry because of adverse economic incentives. The discovery and development of new routes to chemotherapy for Chagas Disease is a clear priority.
Compartir